"This clinical trial is merely one of hundreds of clinical trials," Ringer said. "We want to keep expectations down."
Corey said historically, the odds are against endostatin succeeding.
"Only five to 10 percent of drugs survive human testing," Corey said. "Of those, one in five will turn out to be successful drugs."
Advertisement